A Phase 4 interventional study of Varenicline and Placebo in Smoking Cessation, sponsored by Pfizer. Completed at 37 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 30th largest by enrollment, is one of 7 that started in 2010, is one of 47 in phase 4, and was the 52nd registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 498 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 18th largest by enrollment of the 35 interventional ones that give a count, is one of 6 that started in 2010, is one of 11 in phase 4, and was the 36th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Varenicline
Drug: Placebo
Varenicline 1mg twice daily
Matched placebo twice daily
Continuous Abstinence Rate (CAR) From Week 9 Through Week 12
The percentage of participants who, from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO)\> 10ppm at any visits during this time frame.
Time frame: Week 9 through Week 12
CAR From Week 9 Through Week 52
The percentage of participants who, from Week 9 through Week 52, reported no smoking (Weeks 9 through 52) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 52), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.
Time frame: Week 9 through Week 52
CAR From Week 9 Through Week 24
The percentage of participants who, from Week 9 through Week 24, reported no smoking (Weeks 9 through 24) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 24), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.
Time frame: Week 9 through Week 24
7-day Point Prevalence (PP) of Abstinence at Weeks 12, 24, and 52
The secondary endpoint of 7-day point prevalence of smoking cessation was determined by evaluating a participant's cigarette smoking status, and other nicotine (and/or other tobacco) use, based on the "last 7 days" questions in the Nicotine Use Inventory. Additionally, a participant was not considered a responder if the expired CO was \>10 ppm at the time point being summarized. Participants were considered responders independently at each visit.
Time frame: Weeks 12, 24 and 52
This was a Phase 4, randomized, double-blind, placebo-controlled, parallel group, 2-arm, multicenter study. A total of 498 participants were randomized into the study at 36 investigator sites.
| Milestone | Varenicline | Placebo |
|---|---|---|
| Started | 251 | 247 |
| Completed | 169 | 144 |
| Not completed | 82 | 103 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Did not meet entrance criteria | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Lost to follow-up | 34 | 30 |
| Withdrew: Withdrawal by subject | 29 | 46 |
| Withdrew: Other | 8 | 19 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Randomized but not treated | 2 | 2 |
The percentage of participants who, from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO)\> 10ppm at any visits during this time frame.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Continuous Abstinence Rate (CAR) From Week 9 Through Week 12 | 45.0 | 11.8 |
The percentage of participants who, from Week 9 through Week 52, reported no smoking (Weeks 9 through 52) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 52), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| CAR From Week 9 Through Week 52 | 20.1 | 3.3 |
The percentage of participants who, from Week 9 through Week 24, reported no smoking (Weeks 9 through 24) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 24), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| CAR From Week 9 Through Week 24 | 28.9 | 7.8 |
The secondary endpoint of 7-day point prevalence of smoking cessation was determined by evaluating a participant's cigarette smoking status, and other nicotine (and/or other tobacco) use, based on the "last 7 days" questions in the Nicotine Use Inventory. Additionally, a participant was not considered a responder if the expired CO was \>10 ppm at the time point being summarized. Participants were considered responders independently at each visit.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Week 12 | 53.0 | 14.7 |
| Week 24 | 32.9 | 15.5 |
| Week 52 | 28.9 | 12.2 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline | — | 7/249 (2.8%) | 145/249 (58.2%) |
| Placebo | — | 4/245 (1.6%) | 70/245 (28.6%) |
| Event | Varenicline | Placebo |
|---|---|---|
| Acute coronary syndromeCardiac disorders | 0/249 | 1/245 |
| HypersensitivityImmune system disorders | 1/249 | 1/245 |
| Ligament ruptureInjury, poisoning and procedural complications | 0/249 | 1/245 |
| HyperventilationRespiratory, thoracic and mediastinal disorders | 0/249 | 1/245 |
| Chest painGeneral disorders | 1/249 | 0/245 |
| Allergy to chemicalsImmune system disorders | 1/249 | 0/245 |
| PyelonephritisInfections and infestations | 1/249 | 0/245 |
| Ankle fractureInjury, poisoning and procedural complications | 1/249 | 0/245 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/249 | 0/245 |
| Knee arthroplastySurgical and medical procedures | 1/249 | 0/245 |
| Event | Varenicline | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 66/249 | 22/245 |
| Abnormal dreamsPsychiatric disorders | 36/249 | 0/245 |
| HeadacheNervous system disorders | 26/249 | 24/245 |
| NasopharyngitisInfections and infestations | 19/249 | 17/245 |
| Upper respiratory tract infectionInfections and infestations | 19/249 | 17/245 |
| InsomniaPsychiatric disorders | 17/249 | 0/245 |
| DiarrhoeaGastrointestinal disorders | 15/249 | 0/245 |
| ConstipationGastrointestinal disorders | 13/249 | 0/245 |
| FatigueGeneral disorders | 13/249 | 0/245 |
| Sleep disorderPsychiatric disorders | 13/249 | 0/245 |
| Age, Customized(number of participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| < 18 years | 0 | 0 | 0 |
| 18-44 years | 94 | 94 | 188 |
| 45-64 years | 135 | 139 | 274 |
| >= 65 years | 20 | 12 | 32 |
| Sex: Female, Male(Participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| Female | 125 | 124 | 249 |
| Male | 124 | 121 | 245 |
The record gives a start of Dec 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline